Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Absence seizures

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44256   clinical trials with a EudraCT protocol, of which   7344   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    62 result(s) found for: Absence seizures. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2016-002313-22 Sponsor Protocol Number: ADV6770-A11CS Start Date*: Information not available in EudraCT
    Sponsor Name:ADVICENNE PHARMA SA
    Full Title: A randomised, active controlled, open-label, 2-way cross-over, multicentre study to investigate the palatability, acceptability, pharmacokinetics, safety and tolerability, and treatment compliance ...
    Medical condition: Children with chilhood absence epilepsy.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10000332 Absence seizures HLT
    19.0 10029205 - Nervous system disorders 10034759 Petit mal epilepsy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002484-25 Sponsor Protocol Number: TAK-935-2002(OV935) Start Date*: 2019-04-29
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-935 (OV935) AS AN ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS WITH ...
    Medical condition: Epileptic Encephalitis: Dravet and Lennox Gastuat syndrome (LGS)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-019035-35 Sponsor Protocol Number: A0081194 Start Date*: 2011-02-21
    Sponsor Name:Pfizer Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER TRIAL OF PREGABALIN CONTROLLED RELEASE FORMULATION AS ADJUNCTIVE THERAPY IN ADULTS WITH PARTIAL ONSET SEIZURES - PROTOCO...
    Medical condition: Adjunctive (add on) therapy for adult subjects with partial onset seizures with or without secondary generalization.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10048674 Partial seizures with secondary generalization LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) DE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2017-001514-29 Sponsor Protocol Number: LAM115377 Start Date*: 2017-08-11
    Sponsor Name:GlaxoSmithKline KK
    Full Title: A multi-center, uncontrolled, open-label, evaluation of Lamotrigine monotherapy on newly diagnosed typical absence seizures in children and adolescents
    Medical condition: Typical absence seizure
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000014665 10000331 Absence seizure LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-000265-12 Sponsor Protocol Number: E2007-G000-332 Start Date*: 2011-08-31
    Sponsor Name:Eisai Limited
    Full Title: A Double-blind, Randomized, Placebo-controlled, Multicenter, Parallel-group Study with an Open-label Extension Phase to Evaluate the Efficacy and Safety of Adjunctive Perampanel in Primary Generali...
    Medical condition: Primary Generalized Tonic-Clonic Seizures
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10018101 Generalised tonic-clonic seizures HLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) LV (Completed) GR (Completed) AT (Completed) CZ (Completed) NL (Completed) PL (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2022-001256-42 Sponsor Protocol Number: YKP509C003 Start Date*: 2023-03-08
    Sponsor Name:SK Life Science, Inc
    Full Title: A Randomized, Double-blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Carisbamate (YKP509) as Adjunctive Treatment for Seizures Associated with Lennox-Gastaut Syndrome in C...
    Medical condition: Lennox-Gastaut syndrome (LGS)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10048816 Lennox-Gastaut syndrome PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) GR (Trial now transitioned) IT (Trial now transitioned) PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-016996-31 Sponsor Protocol Number: P09-004 Start Date*: 2010-06-28
    Sponsor Name:Upsher-Smith Laboratories, Inc.
    Full Title: A Randomized, Multicenter, Double-Blind, Placebo–Controlled, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of USL255 as Adjunctive Therapy in Patients with Refractory Partial-O...
    Medical condition: Refractory partial-onset seizures with or without secondary generalization
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10056209 Partial seizures with secondary generalisation PT
    14.0 10029205 - Nervous system disorders 10034090 Partial seizures, complex LLT
    14.0 10029205 - Nervous system disorders 10040703 Simple partial seizures PT
    14.0 10029205 - Nervous system disorders 10048674 Partial seizures with secondary generalization LLT
    14.0 10029205 - Nervous system disorders 10010145 Complex partial seizures PT
    14.0 10029205 - Nervous system disorders 10034091 Partial seizures, simple LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) ES (Completed) GR (Completed) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001337-41 Sponsor Protocol Number: YKP3089C025 Start Date*: 2018-12-17
    Sponsor Name:SK Life Science, Inc.
    Full Title: A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Cenobamate Adjunctive Therapy in Subjects with Primary Generalized Tonic-Clonic Seizures
    Medical condition: Primary Generalized Tonic-Clonic Seizures
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10018101 Generalised tonic-clonic seizures HLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) BG (Completed) CZ (Ongoing) SK (Trial now transitioned) PL (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-003161-40 Sponsor Protocol Number: A0081143 Start Date*: 2007-12-14
    Sponsor Name:Pfizer Inc,East 42nd street,New york, NY10017, USA
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, MULTI-CENTER, COMPARATIVE, FLEXIBLE DOSE TRIAL OF PREGABALIN VERSUS GABAPENTIN AS ADJUNCTIVE THERAPY IN SUBJECTS WITH PARTIAL SEIZURES
    Medical condition: Adjunctive treatment for subjects with partial seizures, with or without secondary generalization.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061334 Partial seizures PT
    9.1 10056209 Partial seizures with secondary generalisation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) ES (Completed) BG (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2013-003771-35 Sponsor Protocol Number: UX007G-CL201 Start Date*: 2014-02-11
    Sponsor Name:Ultragenyx Pharmaceutical Inc
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Study to Assess the Safety and Efficacy of UX007 in Subjects with Glucose Transporter Type 1 Deficiency Syndrome
    Medical condition: Glucose Transporter Type 1 deficiency syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10039911 Seizures (incl subtypes) HLGT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed) FR (Ongoing) HU (Completed) ES (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-017904-95 Sponsor Protocol Number: P09-005 Start Date*: 2010-06-28
    Sponsor Name:Upsher-Smith Laboratories, Inc.
    Full Title: Open-Label Extension Study to Evaluate the Safety of USL255 as Adjunctive Therapy in Patients with Refractory Partial-Onset Seizures who had Participated in P09-004, a Randomized, Multicenter, Doub...
    Medical condition: Refractory partial-onset seizures with or without secondary generalization
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10056209 Partial seizures with secondary generalisation PT
    14.0 10029205 - Nervous system disorders 10034090 Partial seizures, complex LLT
    14.0 10029205 - Nervous system disorders 10040703 Simple partial seizures PT
    14.0 10029205 - Nervous system disorders 10048674 Partial seizures with secondary generalization LLT
    14.0 10029205 - Nervous system disorders 10010145 Complex partial seizures PT
    14.0 10029205 - Nervous system disorders 10034091 Partial seizures, simple LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) ES (Completed) GR (Completed) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004952-30 Sponsor Protocol Number: E2080-J081-304 Start Date*: 2017-02-13
    Sponsor Name:Eisai Co, Ltd.
    Full Title: A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients
    Medical condition: Lennox-Gastaut Syndrome (LSG)
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-005065-64 Sponsor Protocol Number: CBGG492A2202 Start Date*: 2009-03-12
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, double-blind, randomized, placebo-controlled, two-arm parallel-group study of BGG492 as monotherapy in individuals with refractory partial seizures undergoing inpatient evaluation fo...
    Medical condition: Epilepsy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061334 Partial seizures LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-002637-42 Sponsor Protocol Number: EP0165 Start Date*: Information not available in EudraCT
    Sponsor Name:UCB Biopharma SRL
    Full Title: An Open-Label, Multicenter, Outpatient Extension Study to Evaluate the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Se...
    Medical condition: Treatment of stereotypical prolonged seizure
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10076333 Prolonged seizure LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) FR (Not Authorised) HU (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned) BG (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-002750-24 Sponsor Protocol Number: N01269 Start Date*: 2021-04-16
    Sponsor Name:UCB Biopharma SRL
    Full Title: A Randomized, Dose-Finding and Confirmatory, Double-Blind, Placebo-Controlled, Parallel-Group Multicenter Study With a 2-Stage Adaptive Design and Randomized Withdrawal to Evaluate the Efficacy, Sa...
    Medical condition: Childhood absence epilepsy and juvenile absence epilepsy
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: PL (Completed) BE (Completed) IT (Trial now transitioned) SK (Trial now transitioned) Outside EU/EEA RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003441-38 Sponsor Protocol Number: 1042-TSC-3001 Start Date*: Information not available in EudraCT
    Sponsor Name:Marinus Pharmaceuticals Inc.
    Full Title: A Phase 3, Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults with Tuberous Sclerosis Complex (TSC)-related Epilepsy (TrustTSC)
    Medical condition: Tuberous Sclerosis Complex (TSC)-related epilepsy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10032062 Other forms of epilepsy, with intractable epilepsy LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) ES (Ongoing) IT (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001664-38 Sponsor Protocol Number: FFA-MAE Start Date*: 2019-10-02
    Sponsor Name:University Hospital Schleswig-Holstein (UKSH)
    Full Title: A proof of concept and assessment of maximal effect study with low dose Fenfluramine as add-on therapy in Myoclonic Astatic Epilepsy (Doose-Syndrome)
    Medical condition: Childhood epilepsy: Myoclonic Astatic Epilepsy (Doose-Syndrome)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004852 10015040 Epilepsy equivalent LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001770-29 Sponsor Protocol Number: EP0012 Start Date*: 2015-07-06
    Sponsor Name:UCB BIOSCIENCES, Inc.
    Full Title: AN OPEN-LABEL, MULTICENTER EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF LACOSAMIDE AS ADJUNCTIVE THERAPY FOR UNCONTROLLED PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN SUBJECTS W...
    Medical condition: Idiopathic generalized epilepsy
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) HU (Completed) DE (Completed) ES (Ongoing) CZ (Completed) PT (Completed) BE (Completed) PL (Completed) BG (Completed) FR (Completed) RO (Ongoing) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-001997-13 Sponsor Protocol Number: N167 Start Date*: 2004-11-22
    Sponsor Name:UCB S.A. Pharma Sector
    Full Title: An open-label, multicenter, follow-up study to evaluate the safety and efficacy of levetiracetam (LEV) (oral tablets of 166, 250 or 500 mg b.i.d.), at individualized doses up to a maximum of 4000 m...
    Medical condition: Neurology, epilepsy, primary generalized seizures
    Disease: Version SOC Term Classification Code Term Level
    10018079 LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2010-020797-41 Sponsor Protocol Number: NEMO1-08NR26 Start Date*: 2010-11-16
    Sponsor Name:Only for Children Pharmaceuticals
    Full Title: NEMO-1: An open label exploratory dose finding and pharmacokinetic clinical trial of bumetanide for the treatment of NEonatal seizure using Medication Off-patent.
    Medical condition: Neonatal Seizures in Hypoxic Ischemic Encephalopathy
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029205 - Nervous system disorders 10061197 Neonatal seizures LLT
    Population Age: Newborns, Under 18 Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) FI (Prematurely Ended) GB (Prematurely Ended) SE (Prematurely Ended) FR (Ongoing) NL (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA